


<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 378332000900	Application Number 09/183,375
	Applicant  J. SZE BENI et al.	
	Filing Date October 30, 1998	Group Art Unit 1615
	Mailing Date August 31, 2000	



## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
----------------------	-------------	------	--------------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
W	1.	07/31/1997	WO 97/26862	PCT			
	2.	02/23/1994	EP 0 584 001 A1	EPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
W	3.	Decorti et al., 1996 "Effect of Paclitaxel and Cremophor EL on Mast Cell Histamine Secretion and Their Interaction with Adriamycin" Anticancer Research 16: 317-320
I	4.	Eisenhauer et al., 1994 "European-Canadian Randomized Trial of Paclitaxel in Relapsed Ovarian Cancer: High-Dose Versus Low-Dose and Long Versus Short Infusion" Journal of Clinical Oncology, 12(12): 2654-2666
	5.	Essayan et al., 1996 "Successful Parenteral Desensitization to Paclitaxel" Journal of Allergy Clinical Immunology, 97(1): 42-46
	6.	Hammerschmidt et al., 1980 "Association of Complement Activation and Elevated Plasma-C5a With Adult Respiratory Distress Syndrome" The Lancet, May 3, 1980: 947-949
	7.	Marceau et al., 1987 "Effects of the Anaphylatoxins on Circulation" Immunopharmacology, 14: 67-84
	8.	Michaud, 1997 "Methods for Preventing Reactions Secondary to Cremophor EL" Annals of Pharmacotherapy, 31(11): 1402-1404
	9.	O'Brien et al., 1992 "Allergic Reactions to Cytotoxic Drugs - an Update" Annals of Oncology, 3: 605-610
	10.	Szebeni, 1998 "The Interaction of Liposomes with the Complement System" Critical Reviews in Therapeutic Drug Carrier Systems, 15(1): 57-88
	11.	Szebeni et al, 1998 "Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study" Journal of the National Cancer Institute, 90(4): 300-306

EXAMINER: (examiner)



W


DATE CONSIDERED:

3/81

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 378332000900	Application Number 09/183,375
	Applicant  J. SZE BENI et al.	
	Filing Date October 30, 1998	Group Art Unit 1615
	Mailing Date August 31, 2000	

	12.	Szebeni et al., 1997 "Complement Activation In Vitro by the Red Cell Substitute, Liposome-encapsulated Hemoglobin: Mechanism of Activation and Inhibition by Soluble Complement Receptor Type 1" Transfusion, 37(2): 150-159
	13.	Szebeni et al., 1997) "Complement Activation and Thromboxane Secretion by Liposome-Encapsulated Hemoglobin in Rats In Vitro: Inhibition by Soluble Complement Receptor Type 1" Art., Cells, Blood Subs., and Immob. Biotech., 25(4): 347-355
	14.	Terwogt et al, 1997 "Alternative Formulations of Paclitaxel" Cancer Treatment Reviews 23(2): 87-95
	15.	Wassef et al., 1989 "Anaphylactoid Reactions Mediated by Autoantibodies to Cholesterol in Miniature Pigs" The Journal of Immunology 143(8): 2990-2995
	16.	Weiss et al., 1990 "Hypersensitivity Reactions From Taxol" Journal of Clinical Oncology, 8(7): 1263-1268

EXAMINER: 	DATE CONSIDERED: 3   0
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	